Rize Oncology Inc.
CNSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -3.30% | 10.47% | 20.06% | 8.63% | 34.46% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.01% | 74.98% | 113.17% | 62.13% | 49.46% |
| Operating Income | -8.01% | -74.98% | -113.17% | -62.13% | -49.46% |
| Income Before Tax | -10.33% | -81.23% | -127.17% | -73.15% | -62.03% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.33% | -81.23% | -127.17% | -73.15% | -62.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.33% | -81.23% | -127.17% | -73.15% | -62.03% |
| EBIT | -8.01% | -74.98% | -113.17% | -62.13% | -49.46% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 18.67% | -12.06% | -16.20% | -1.68% | -9.21% |
| Normalized Basic EPS | 18.27% | -12.50% | -18.18% | -2.70% | -10.64% |
| EPS Diluted | 18.67% | -12.06% | -16.20% | -1.68% | -9.21% |
| Normalized Diluted EPS | 18.27% | -12.50% | -18.18% | -2.70% | -10.64% |
| Average Basic Shares Outstanding | 41.20% | 65.27% | 96.68% | 69.27% | 36.57% |
| Average Diluted Shares Outstanding | 41.20% | 65.27% | 96.68% | 69.27% | 36.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |